Author

E. J. Pomeroy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:genetic perturbation / CRISPR· 3 Research Focus:cell type annotation· 2 Assay:CRISPR screen· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1

Frequent Co-Authors

B. R. Webber· 4 shared B. S. Moriarity· 4 shared W. S. Lahr· 3 shared B. Walcheck· 2 shared J. B. Krueger· 2 shared J. G. Skeate· 2 shared J. S. Miller· 2 shared M. Felices· 2 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

B. R. Webber

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing

M. Wang, J. B. Krueger, A. K. Gilkey, E. M. Stelljes, M. G. Kluesner, E. J. Pomeroy, J. G. Skeate, N. J. Slipek, W. S. Lahr, P. N. Claudio Vazquez, Y. Zhao, E. J. Eaton, K. Laoharawee, B. R. Webber, B. S. Moriarity

This study enhances CAR-NK cell functionality using non-viral base editing and transposon integration, showing improved therapeutic potential in Burkitt's lymphoma models.

bioRxiv · Mar 5, 2024Bioengineering

Ablation of SYK kinase from primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production

J. D. Dahlvang, J. K. Dick, J. A. Sangala, E. J. Pomeroy, K. M. Snyder, J. M. Moushon, C. E. Thefaine, J. Wu, S. E. Hamilton, M. Felices, J. S. Miller, B. Walcheck, B. R. Webber, B. S. Moriarity, G. T. Hart

This study ablates SYK kinase in primary human NK cells using CRISPR/Cas9, finding it enhances cytotoxicity and cytokine production compared to other gene ablations.

bioRxiv · May 29, 2022 · PreprintImmunology

Non-Viral Engineering of CAR-NK and CAR-T cells using the Tc Buster Transposon System™

E. J. Pomeroy, W. S. Lahr, J. W. Chang, J. B. Krueger, B. J. Wick, N. J. Slipek, J. G. Skeate, B. R. Webber, B. S. Moriarity

This paper demonstrates a non-viral method using the Tc Buster transposon system to deliver CAR constructs to primary human NK and T cells, achieving efficient gene expression and functional activity.

bioRxiv · Aug 2, 2021 · PreprintBioengineering

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

E. J. Pomeroy, J. T. Hunzeker, M. T. Kluesner, M. R. Crosby, W. S. Lahr, L. Bendzick, J. S. Miller, B. R. Webber, M. A. Geller, B. Walcheck, M. Felices, T. K. Starr, B. S. Moriarity

This paper develops a CRISPR/Cas9-based method to edit human NK cells, enhancing their anti-cancer activity by knocking out ADAM17 and PD1.

bioRxiv · Sep 29, 2018Immunology